Results 111 to 120 of about 71,892 (273)

Phenotypic Characterization of Replication‐Impaired Lenacapavir‐Resistant HIV Clinical Isolates

Journal of Medical Virology, Volume 97, Issue 4, April 2025.
ABSTRACT Lenacapavir (LEN) is a potent, first‐in‐class long‐acting HIV‐1 capsid (CA) inhibitor, approved for treatment of people with multi‐drug resistant HIV in combination with other antiretrovirals. In clinical studies with LEN, the CA resistance‐associated mutations (RAMs) M66I, Q67H/K/N, K70H/N/R/S, N74D/H/K, A105S/T, and T107A/C/N/S were observed.
Sally Demirdjian, Vidula Naik, Nicolas Margot, Brie Falkard, Christian Callebaut   +4 more
wiley   +1 more source

The Peptide PROTAC Modality: A New Strategy for Drug Discovery

MedComm, Volume 6, Issue 4, April 2025.
Peptide PROTAC is a bifunctional molecule generally composed of a target protein binding peptide (TBP), a linker peptide (LP), an E3 ligase binding peptide (EBP), and a delivery‐enhancing peptide (DEP), which can bind to the target protein (P) and E3 ligase (E3), inducing P to be labeled with ubiquitin (Ub) and subsequently recognized and degraded by ...
Youmin Zhu, Yu Dai, Yuncai Tian
wiley   +1 more source

First report of computational protein-ligand docking to evaluate susceptibility to HIV integrase inhibitors in HIV-infected Iranian patients. [PDF]

Biochem Biophys Rep, 2022
Ghasabi F, Hashempour A, Khodadad N, Bemani S, Keshani P, Shekiba MJ, Hasanshahi Z.   +6 more
europepmc   +1 more source

Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders

Cell Proliferation, Volume 58, Issue 4, April 2025.
This review outlines the latest research advancements in prime editing technology, delivery strategies, and the challenges that must be addressed to fully realize its therapeutic potential, emphasizing the high potential of prime editing in the remission or cure of genetic diseases. ABSTRACT Genetic diseases have long posed significant challenges, with
Mengyao Li, Yi Lin, Qiang Cheng, Tuo Wei
wiley   +1 more source

Design, Synthesis and Anti-HIV Integrase Evaluation of N-(5-Chloro-8-Hydroxy-2-Styrylquinolin-7-yl)Benzenesulfonamide Derivatives

Molecules, 2010
Styrylquinoline derivatives are demonstrated to be HIV-1 integrase inhibitors. On the basis of our previous CoMFA analysis of a series of styrylquinoline derivatives, N-[(2-substituted-styryl)-5-chloro-8-hydroxyquinolin-7-yl]-benzenesulfonamide ...
Li-Ming Hu, Jian-Jun Tan, Cheng-Chu Zeng, Hong-Qiu He, Zi-Guo Jiao, Cun-Xin Wang   +5 more
doaj   +1 more source

Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes. [PDF]

Cells, 2022
Ngono Ayissi K, Gorwood J, Le Pelletier L, Bourgeois C, Beaupère C, Auclair M, Foresti R, Motterlini R, Atlan M, Barrail-Tran A, Le Grand R, Desjardins D, Fève B, Lambotte O, Capeau J, Béréziat V, Lagathu C.   +16 more
europepmc   +1 more source

Point‐of‐care nucleic acid testing – a step forward in controlling the HIV epidemic: A review

HIV Medicine, Volume 26, Issue 4, Page 536-545, April 2025.
Abstract Introduction The HIV/AIDS epidemic, with 85.6 million infections and 40.4 million AIDS‐related deaths globally, remains a critical public health challenge. Current diagnostic methods, primarily fourth‐generation immunoassays, have limitations due to their long window periods, and most viral load assays require centralized testing protocols ...
Suleyman Sarp Pinar, Mark Manak, Shanmugam Saravanan, Nesrina Imami, Catherine Kibirige   +4 more
wiley   +1 more source

Classification of Tangle Solutions for Integrases, A Protein Family that Changes DNA Topology [PDF]

arXiv, 2005
Integrase proteins acting on circular double-stranded DNA often change its topology by transforming unknotted circles into torus knots and links. Two systems of tangle equations--corresponding to the two initial DNA sequences--arise when modelling this transformation: direct and inverted.
arxiv  

Prevalence and determinants of resistance mutations in HIV‐1‐infected patients exposed to integrase inhibitors in a large Italian cohort

HIV Medicine, 2018
The aim of the study was to analyse the prevalence of integrase resistance mutations in integrase strand transfer inhibitor (INSTI)‐experienced HIV‐1‐infected patients and its predictors.
S. Modica, B. Rossetti, F. Lombardi, F. Lagi, M. Maffeo, R. D'Autilia, M. Pecorari, I. Vicenti, Bianca Bruzzone, G. Magnani, Stefania Paolucci, D. Francisci, G. Penco, D. Sacchini, Maurizio Zazzi, A. D. Luca, A. Biagio   +16 more
semanticscholar   +1 more source

A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda

HIV Medicine, Volume 26, Issue 4, Page 592-605, April 2025.
Abstract Introduction Dolutegravir is now extensively used in sub‐Saharan Africa as a preferred component of antiretroviral therapy (ART). There is a paucity of large studies using routinely collected data from African people living with HIV on dolutegravir‐based regimens to inform HIV programmes.
Eva Agnes Laker Odongpiny, Melanie Nicol, Elizabeth Katana, Joseph Owori, Allan Buzibye, Kay Sedan, Mike Kesby, Matthew Holden, Noela Owarwo, David Meya, Barbara Castelnuovo, Derek J. Sloan, Christine Sekaggya   +12 more
wiley   +1 more source